1,695 results on '"Kawaoka, Yoshihiro"'
Search Results
2. Highly pathogenic H5N1 avian influenza virus outbreak in cattle: the knowns and unknowns
3. A compendium of multi-omics data illuminating host responses to lethal human virus infections
4. Attenuation of A(H7N9) influenza virus infection in mice exposed to cigarette smoke
5. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
6. Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine
7. Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV
8. An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants
9. A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters
10. Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65–85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial
11. Drug susceptibility and the potential for drug-resistant SARS-CoV-2 emergence in immunocompromised animals
12. Host range, transmissibility and antigenicity of a pangolin coronavirus
13. Defining the risk of SARS-CoV-2 variants on immune protection
14. Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses
15. Glyco-engineered MDCK cells display preferred receptors of H3N2 influenza absent in eggs used for vaccines
16. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
17. Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
18. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates
19. Identification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2
20. Plasminogen activator inhibitor 1 is not a major causative factor for exacerbation in a mouse model of SARS-CoV-2 infection
21. Correlation Analysis between Gut Microbiota Alterations and the Cytokine Response in Patients with Coronavirus Disease during Hospitalization.
22. Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge
23. Tracing the origin of SARS-CoV-2 omicron-like spike sequences detected in an urban sewershed: a targeted, longitudinal surveillance study of a cryptic wastewater lineage
24. Assessment of the antigenic evolution of a clade 6B.1 human H1N1pdm influenza virus revealed differences between ferret and human convalescent sera
25. Characterization of a human H3N8 influenza virus
26. Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan
27. Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate
28. Isolation of Bat Sarbecoviruses, Japan
29. Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022
30. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents
31. Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination
32. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters
33. Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents
34. In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters
35. High titers of infectious SARS-CoV-2 in corpses of patients with COVID-19
36. Multi-omics of NET formation and correlations with CNDP1, PSPB, and L-cystine levels in severe and mild COVID-19 infections
37. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters
38. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2
39. COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions
40. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
41. Characterization of a new SARS-CoV-2 variant that emerged in Brazil
42. mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
43. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
44. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
45. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
46. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
47. Sialylated and sulfated N-Glycans in MDCK and engineered MDCK cells for influenza virus studies
48. A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases
49. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
50. Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.